Core Insights - Ascletis Pharma Inc. announced that denifanstat (ASC40), a first-in-class oral fatty acid synthase (FASN) inhibitor, successfully met all primary and secondary endpoints in a Phase III clinical trial for moderate to severe acne vulgaris [1][6][10] Clinical Trial Overview - The Phase III trial was a randomized, double-blind, placebo-controlled study conducted in China with 480 patients, comparing 50 mg denifanstat to a placebo over 12 weeks [2] - Baseline characteristics were well balanced between the treatment and placebo groups, with total lesion counts of 102.2 for denifanstat and 102.1 for placebo [11] Efficacy Results - Primary endpoints showed a treatment success rate of 33.2% for denifanstat versus 14.6% for placebo (p<0.0001) [3] - Denifanstat achieved a 57.4% reduction in total lesion count compared to 35.4% for placebo (p<0.0001) and a 63.5% reduction in inflammatory lesions compared to 43.2% for placebo (p<0.0001) [3] - Key secondary endpoint results included a 51.9% reduction in non-inflammatory lesions for denifanstat versus 28.9% for placebo (p<0.0001) [3] Safety Profile - Denifanstat demonstrated a favorable safety and tolerability profile, with treatment-emergent adverse events (TEAEs) comparable to placebo [4] - No TEAEs related to denifanstat exceeded 10%, and all reported adverse events were mild or moderate [4] Mechanism of Action - Denifanstat works by directly inhibiting facial sebum production and inflammation, addressing the underlying causes of acne [5] - This mechanism differentiates denifanstat from other acne treatments that do not target the root cause of the condition [5] Comparative Efficacy - In non-head-to-head comparisons, denifanstat was found to be 98% and 178% more effective than sarecycline and doxycycline, respectively, in terms of placebo-adjusted treatment success [7][8] - Denifanstat was also 60% more effective than clascoterone cream regarding treatment success [7][8] Market Potential - Denifanstat is positioned as a first-in-class oral acne therapeutic with exceptional efficacy and a favorable safety profile, potentially improving patient compliance compared to topical treatments [9] - The company plans to submit denifanstat for approval to the China National Medical Products Administration (NMPA) [6]

Core Viewpoint - Sagimet Biosciences Inc. is advancing its clinical-stage drug denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), with new data presentations scheduled at the EASL Congress 2025 [1][6]. Group 1: EASL Presentation Details - Three poster presentations will feature analyses from the Phase 2b FASCINATE-2 study of denifanstat, focusing on its efficacy in treating MASH [1]. - The first presentation will assess the MASH Resolution Index (MR-I) as a non-invasive biomarker for predicting histological response to denifanstat, indicating its potential to identify non-responders [2]. - The second presentation highlights the correlation between reduced plasma glycine- and taurine-conjugated bile acids and histological improvements in MASH patients treated with denifanstat [3]. - The third presentation discusses denifanstat's antifibrotic effects on collagen features linked to major adverse liver outcomes in high-risk patients [4]. Group 2: Company Overview - Sagimet is focused on developing fatty acid synthase (FASN) inhibitors, with denifanstat being its lead candidate, designed for once-daily oral administration [5]. - Denifanstat has received Breakthrough Therapy designation from the FDA for treating non-cirrhotic MASH with moderate to advanced liver fibrosis [6]. - The global prevalence of MASH is significant, affecting over 115 million people, with limited treatment options currently available [7].

Core Insights - Sagimet Biosciences has initiated its Phase 3 denifanstat program for metabolic dysfunction-associated steatohepatitis (MASH) with patient screening expected to start in the first half of 2025 [1][2] - The FDA has granted Breakthrough Therapy designation to denifanstat for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis [3][8] - The company has received clearance for its Investigational New Drug (IND) application for TVB-3567, a second fatty acid synthase (FASN) inhibitor aimed at treating moderate to severe acne [1][3] Clinical and Regulatory Updates - The Phase 3 program for denifanstat will include two trials: FASCINATE-3 for patients with F2/F3 (non-cirrhotic) MASH and FASCINIT for patients with suspected or confirmed MASLD/MASH [3][4] - Positive topline results from the Phase 2b FASCINATE-2 trial were reported in January 2024, demonstrating significant improvements in disease activity and fibrosis [3][4] - The company plans to initiate a first-in-human Phase 1 trial for TVB-3567 in 2025 following IND clearance [3][4] Financial Results - As of December 31, 2024, Sagimet reported cash, cash equivalents, and marketable securities totaling $158.7 million, expected to fund operations for at least the next 12 months [6][14] - Research and development expenses for the year ended December 31, 2024, were $38.4 million, compared to $19.8 million in 2023 [6][13] - The net loss for the year ended December 31, 2024, was $45.6 million, an increase from $27.9 million in 2023 [6][13] Corporate Updates - Sagimet has made several key appointments to its board of directors throughout 2024, including industry leaders [3][4] - The company completed a follow-on offering of 9 million shares in January 2024, resulting in net proceeds of $104.7 million [3][4] - The company is advancing both denifanstat and TVB-3567 in the coming year, highlighting the potential of FASN inhibition across multiple disease states [2][3]

Core Insights - Sagimet Biosciences Inc. is focused on developing fatty acid synthase (FASN) inhibitors to address conditions related to excessive fatty acid palmitate production, with Denifanstat being the primary value driver [1] Company Overview - Sagimet Biosciences Inc. trades on NASDAQ under the ticker SGMT and has been under observation since April of the previous year [1] Product Development - The company is advancing its research on FASN inhibitors, which are aimed at treating specific health conditions linked to fatty acid production [1]